Transgene and NEC extend collaboration to continue joint clinical development of neoantigen cancer vaccine
时间:2024-09-29 04:32:56 阅读(143)
Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation, a leader in IT, network and AI technologies, on Thursday announced the signing of a further development collaboration agreement to continue the clinical evaluation of the individualized neoantigen cancer vaccine TG4050.
TG4050 is currently being evaluated in a randomized multicenter Phase I trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers. Based on promising data obtained in this Phase I[1] trial (NCT04183166), Transgene and NEC are preparing a randomized Phase I/II extension of this trial slated to start in 2024. This new trial builds on compelling first signs of efficacy and induction of specific T-cell responses to generate a comprehensive set of immunological and clinical data to further demonstrate the potential of TG4050.
“We are pleased to announce the extension of our agreement with NEC, which marks a significant milestone in our collaboration. We are looking forward to continuing to treat patients with our individualized cancer vaccine TG4050. The compelling initial Phase I data presented with NEC at ASCO 2023 showed that all evaluable patients treated with TG4050 monotherapy developed a specific immune response and remained disease-free. Our joint clinical development plan builds on these promising data in a setting where there is no approved treatment to prevent patient relapse after adjuvant chemoradiotherapy. We believe that TG4050, by combining a powerful and immunogenic viral vector with an extremely sophisticated neoantigen selection tool, has the potential to address major medical needs in the adjuvant treatment of solid tumors,” Alessandro Riva, Chairman and CEO of Transgene, said.
TG4050 is based on Transgene’s viral vector based myvac platform and powered by NEC’s cutting-edge AI capabilities for the identification and prediction of the most immunogenic neoantigens.
Masamitsu Kitase, Corporate SVP, Head of Healthcare and Life Sciences Division, NEC Corporation, commented: “Transgene has been our trusted partner in developing our joint neoantigen asset TG4050. I am excited that the positive results from the Phase I study have encouraged us to further collaborate on this very promising asset for treating head and neck cancers. We are happy that our state-of-the-art artificial intelligence (AI)/ machine learning (ML) models help in predicting clinically meaningful neoantigens which impact patient outcomes. NEC’s Healthcare and Life Sciences Division is committed to bringing novel AI-based treatments to patients across the globe and achieving meaningful advances in the pharmaceutical industry.”
猜你喜欢
- Defence stocks in focus amidst global uncertainty- Is it an opportunity for invest-
- Defence-related stocks get indigenisation boost
- Dhanlaxmi Bank shareholders question rights issue plan
- Rating- Buy; Apollo Hospitals- Boost to pharmacy network expansion
- Rakesh Jhunjhunwala, wife sell Delta Corp shares, trim holdings; stock tanks 20% this month
- Despite a strong dollar, high treasury yields, rupee clocks gains; rupee futures to trade in 83
- Domestic investor share in NSE firms hits all-time high
- DreamFolks debuts at 56% premium on bourses
- Day after deal, GCPL & Raymond dip up to 9%